Now called Comirnaty, the vaccine is approved for those 16 years and older.
The FDA’s full approval of Pfizer and BioNTech’s COVID-19 vaccine is expected to boost vaccination rates in the United States, health care groups say.
In a joint statement, the American Medical Association, the American Hospital Association, and the American Nurses Association lauded the approval of the vaccine, now called Comirnaty, to prevent COVID-19 in people 16 and older.
The vaccine also continues to be available under emergency use authorization (EUA), including for adolescents 12 through 15 years of age, as well as for a third dose in certain immunocompromised individuals, the FDA said in a press release.
“The FDA’s approval of this vaccine is a milestone as we continue to battle the COVID-19 pandemic. While this and other vaccines have met the FDA’s rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product,” Acting FDA Commissioner Janet Woodcock, M.D., said in a statement.
According to recent polling, 30% of unvaccinated people said they were waiting for vaccines to receive full approval before getting vaccinate.
“While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the United States,” Woodcock said
The FDA’s full approval is the result of “many months of work, robust data evaluation, and a thorough, comprehensive review process” and is a “major step forward in the worldwide effort to end this pandemic,” AHA, ANA and AMA said.
“The vaccines to prevent COVID-19 are effective; we have known that for months as health care professionals were among the first to get vaccinated and have advocated for our patients to get vaccinated to save lives,” the health organizations said. “But today’s news marks a critical moment for people who were concerned about getting vaccinated due to the vaccines being authorized for emergency use. With millions of data points on the vaccine’s safety and efficacy over nearly nine months of vaccinations, every ‘i’ is dotted and every ‘t’ is crossed. This vaccine is safe, it prevents severe COVID-19, hospitalization, and deaths, and it will save your life.”
FDA’s approval also should further reinforce efforts in the health care field to urge vaccination, and to “deploy all reasonable tools to achieve high levels of vaccination, including mandatory vaccination policies,” AMA, AHA and AHA said.
Diego R. Hijano, MD, a pediatric infectious disease specialist at St. Jude Children’s Research Hospital in Memphis, is also encouraging all parents and eligible children to get the vaccine.
“As the Delta variant continues to surge, America’s children are in a very dangerous situation, with record numbers being hospitalized around the country,” Hijano said in a press release. Received it via email. “With the FDA’s full approval of the Pfizer COVID vaccine today, it should give hesitant parents more confidence in the safety and effectiveness of the vaccine; there is no reason not to get yourself and your child vaccinated against the COVID virus.”
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More